Clinical Trial: Using a Triple Combo (Elotuzumab, Lenalidomide and Dex) Before and After Transplant for Newly Diagnosed Myeloma
Myeloma specialists are finding that the triple combinations are more effective than doublets in the treatment of multiple myeloma. Investigators want to know if using these triplets, especially those that include an immunotherapy like the monoclonal antibody elotuzumab (Empliciti) will improve outcomes for newly diagnosed patients who will receive a stem cell transplant.
In this Phase II study open at five centers, the triplet of elotuzumab, lenalidomide and dexamethasone will be used as induction therapy before transplant, and as consolidation therapy and maintenance after transplant for newly diagnosed myeloma patients.
To learn more, click the link below:
Elo/Len/Dex Myeloma Clinical Trial
